SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Monogram Biosciences, Inc. (Nasdaq:MGRM) announced that new results from a study of the predictive power of its HERmark™ Breast Cancer Assay were presented at the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas. An oral presentation, entitled “HER2 Protein expression and homodimer levels predict response to trastuzumab in centrally tested FISH-positive metastatic breast cancer patients”, was made by Allan Lipton M.D., Professor of Medicine & Oncology at Hershey Medical Center/Penn State University.
